| BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) |
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) in adolescents and people with severe HAE showing significant and sustained reductions in HAE attack rates through 18 months of follow-up after beginning treatment with ORLADEYO in both patient populations. |
globenewswire.com |
2025-05-16 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years |
–FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025– – ORLADEYO would be the first targeted oral prophylactic therapy for patients with HAE under the age of 12, if approved – RESEARCH TRIANGLE PARK, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for the use of oral, once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to 11 years. |
globenewswire.com |
2025-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for May 9th |
BCRX, WYY and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2025. |
zacks.com |
2025-05-09 15:00:47 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for May 9th |
CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025. |
zacks.com |
2025-05-09 12:10:40 |
Czytaj oryginał (ang.) |
| Why BioCryst (BCRX) Might be Well Poised for a Surge |
BioCryst (BCRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2025-05-08 17:20:37 |
Czytaj oryginał (ang.) |
| What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now? |
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2025-05-08 17:00:48 |
Czytaj oryginał (ang.) |
| Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect? |
The mean of analysts' price targets for BioCryst (BCRX) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-08 14:55:44 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors |
BioCryst Pharmaceuticals, Inc. BCRX on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the consensus of $126.87 million. |
benzinga.com |
2025-05-05 21:29:26 |
Czytaj oryginał (ang.) |
| BioCryst: Strong Opportunity For A Double With A Proven Therapy |
BioCryst Pharmaceuticals' flagship product ORLADEYO shows remarkable growth, maintaining a persistent upward trajectory since its launch in 2020, and is expected to continue into 2025. Despite heavy reliance on ORLADEYO, BCRX stock remains a "Buy" due to its strong market presence and growth potential in the hereditary angioedema therapy market. The 10-K report highlights competition, including late-stage therapies and an upcoming PDUFA date for KalVista's sebetralstat, which could impact market dynamics. |
seekingalpha.com |
2025-05-05 18:05:10 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript |
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Steven Seedhouse - Cantor Maury Raycroft - Jefferies Jessica Fye - JP Morgan Stacy Ku - TD Cowen Gena Wang - Barclays Laura Chico - Wedbush Securities Liisa Bayko - Evercore ISI Serge Belanger - Needham & Co. Jonathan Wolleben - Citizens JMP Operator Good day, and welcome to the BioCryst First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-05-05 16:54:58 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 |
BioCryst Pharmaceuticals (BCRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago. |
zacks.com |
2025-05-05 13:20:34 |
Czytaj oryginał (ang.) |
| BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update |
—Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down $75 million of debt; saves approximately $23.5 million over life of loan— —NDA submitted for ORLADEYO oral granules for children with HAE aged 2-11— —U.S. IND open for BCX17725 for Netherton syndrome— RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. |
globenewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
RESEARCH TRIANGLE PARK, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 48,000 shares of BioCryst common stock. The RSUs were granted as of May 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-05-02 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Appoints Steve Frank to Board of Directors |
RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. |
globenewswire.com |
2025-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst to Present at Upcoming Investor Conferences |
RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: |
globenewswire.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-28 15:05:56 |
Czytaj oryginał (ang.) |
| BioCryst to Report First Quarter 2025 Financial Results on May 5 |
RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025. |
globenewswire.com |
2025-04-21 11:00:00 |
Czytaj oryginał (ang.) |
| How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry |
BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. |
zacks.com |
2025-04-10 22:25:29 |
Czytaj oryginał (ang.) |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,500 shares of BioCryst common stock. The RSUs were granted as of April 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-04 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst to Present at Upcoming Investor Conference |
RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 9:30 a.m. ET. |
globenewswire.com |
2025-04-02 20:01:00 |
Czytaj oryginał (ang.) |
| BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates |
Although the revenue and EPS for BioCryst (BCRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-27 13:31:08 |
Czytaj oryginał (ang.) |
| Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher |
After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
zacks.com |
2025-02-26 13:01:21 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-02-26 12:56:16 |
Czytaj oryginał (ang.) |
| BioCryst: Orladeyo's Expansion Is Just Getting Started |
BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO, a healthy cash position, and a promising pipeline, making it an attractive investment. Despite a net loss, BioCryst's improved operating metrics and strategic focus on key assets like BCX17725 and avoralstat signal disciplined resource allocation and long-term growth. ORLADEYO's potential pediatric expansion could significantly boost market penetration and revenue, positioning BioCryst as a leader in hereditary angioedema treatment. |
seekingalpha.com |
2025-02-26 11:09:48 |
Czytaj oryginał (ang.) |
| BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up |
BioCryst Pharmaceuticals stock rose 9% since September, driven by strong Orladeyo sales and raised revenue guidance for 2025 to $535-$550 million. Orladeyo's convenience over injectable therapies is solidifying its market presence, with pediatric expansion and exclusivity until 2035 boosting growth prospects. Potential competition from Pharvaris' deucrictibant, but Orladeyo's market entrenchment and differentiation mitigate immediate threats. |
seekingalpha.com |
2025-02-26 09:45:00 |
Czytaj oryginał (ang.) |
| BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical |
I initially rated BioCryst a "Sell" in November 2023, but am now upgrading to "Hold" as the company has outperformed my expectations, despite competitive pressures. Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition and may not reach management's $1bn annual revenue target in my view. Q4 2024 earnings showed a notable improvement with a reduced GAAP operating loss and a positive non-GAAP operating profit, but guidance for ~22% growth led to a sell-off. |
seekingalpha.com |
2025-02-25 20:24:18 |
Czytaj oryginał (ang.) |
| Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today |
Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (BCRX -9.99%) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024 results, they traded its shares down by an even 10% on the day. |
fool.com |
2025-02-24 20:15:51 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript |
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q4 2024 Earnings Conference Call February 24, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Anthony Doyle - CFO Conference Call Participants Tazeen Ahmad - Bank of America Jessica Fye - JP Morgan Stacy Ku - TD Cowen Brian Abrahams - RBC Capital Markets Gena Wang - Barclays Jonathan Wolleben - Citizens JMP Seema Sheoran - Evercore ISI Serge Belanger - Needham & Company Maury Raycroft - Jefferies Operator Good morning, and welcome to the BioCryst Fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-02-24 14:17:23 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings |
On Monday, BioCryst Pharmaceuticals, Inc. BCRX released results from an interim analysis of the ongoing APeX-P trial. |
benzinga.com |
2025-02-24 13:49:14 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates |
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.28 per share a year ago. |
zacks.com |
2025-02-24 11:10:28 |
Czytaj oryginał (ang.) |
| BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones |
—ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— |
globenewswire.com |
2025-02-24 09:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to |
– Additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-INH deficiency and normal C1-INH levels and function – |
globenewswire.com |
2025-02-24 08:00:00 |
Czytaj oryginał (ang.) |
| BioCryst to Present at Upcoming Investor Conferences |
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: |
globenewswire.com |
2025-02-19 09:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-17 13:06:35 |
Czytaj oryginał (ang.) |
| BioCryst Launches ORLADEYO® (berotralstat) in Portugal |
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Portugal will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks. |
globenewswire.com |
2025-02-12 09:00:00 |
Czytaj oryginał (ang.) |
| BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress |
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new clinical and real-world outcomes with oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) joint congress. |
globenewswire.com |
2025-02-10 10:30:00 |
Czytaj oryginał (ang.) |
| BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 |
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025. |
globenewswire.com |
2025-02-10 09:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees stock options to purchase an aggregate of 22,575 shares, and restricted stock units (RSUs) covering an aggregate of 27,550 shares, of BioCryst common stock. The options and RSUs were granted as of January 31, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-04 09:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) |
—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB ® ) expected to be between $540-$560 million in 2025— —Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025— —New drug application planned in 2025 for ORLADEYO granules in children up to age 12; will address significant unmet need— —Pipeline advancing into patients with Netherton syndrome (BCX17725) and diabetic macular edema (avoralstat) in 2025— RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO® (berotralstat) net revenue and total revenue for the fourth quarter and full year 2024. |
globenewswire.com |
2025-01-10 09:00:00 |
Czytaj oryginał (ang.) |
| BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference |
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET. |
globenewswire.com |
2025-01-07 09:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy |
BioCryst remains a "Buy" due to ORLADEYO's proven success, potential growth, and management's confidence despite significant competition and a one-dimensional revenue stream. Q3 2024 showed mixed results with a modest revenue beat and slight earnings miss, leading to a 13% stock drop on higher volume. ORLADEYO's revenue guidance is strong, with expectations of reaching $1 billion annually by 2029, driven by its convenience and efficacy. |
seekingalpha.com |
2024-12-09 15:47:29 |
Czytaj oryginał (ang.) |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees stock options to purchase an aggregate of 17,400 shares, and restricted stock units (RSUs) covering an aggregate of 12,150 shares, of BioCryst common stock. The options and RSUs were granted as of November 29, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-04 18:15:00 |
Czytaj oryginał (ang.) |
| BioCryst Launches ORLADEYO® (berotralstat) in Ireland |
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks. |
globenewswire.com |
2024-11-18 04:00:00 |
Czytaj oryginał (ang.) |
| BioCryst to Present at Upcoming Investor Conferences |
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: |
globenewswire.com |
2024-11-06 09:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees stock options to purchase an aggregate of 18,200 shares, and restricted stock units (RSUs) covering an aggregate of 12,750 shares, of BioCryst common stock. The options and RSUs were granted as of October 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-11-05 09:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript |
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Jinky Rosselli - Chief Data and Insights Officer Conference Call Participants Nick Lenard - JPMorgan Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Maury Raycroft - Jefferies Stacy Ku - TD Cowen Liisa Bayko - Evercore ISI Gena Wang - Barclays Serge Belanger - Needham & Company Operator Good day and Welcome to the BioCryst Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. |
seekingalpha.com |
2024-11-04 13:00:33 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates |
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2024-11-04 11:10:27 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5% |
The consensus price target hints at a 79.5% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-10-23 14:56:13 |
Czytaj oryginał (ang.) |
| BioCryst to Report Third Quarter 2024 Financial Results on November 4 |
RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on Monday, November 4, 2024. |
globenewswire.com |
2024-10-21 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat) |
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reductions in hospitalizations, emergency room visits and use of on-demand therapies, after beginning treatment with ORLADEYO. |
globenewswire.com |
2024-10-14 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst (BCRX) Upgraded to Buy: Here's Why |
BioCryst (BCRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-10-07 17:01:43 |
Czytaj oryginał (ang.) |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 21 newly-hired employees stock options to purchase an aggregate of 71,175 shares, and restricted stock units (RSUs) covering an aggregate of 50,025 shares, of BioCryst common stock. The options and RSUs were granted as of September 30, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-10-03 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome |
—Potential best-in-class targeted treatment for Netherton syndrome is company's first protein therapeutic to advance to the clinic— |
globenewswire.com |
2024-10-02 11:00:00 |
Czytaj oryginał (ang.) |
| U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile |
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has awarded BioCryst up to a $69 million contract for the procurement of up to 95,625 doses over a five-year period of RAPIVAB® (peramivir injection) for the treatment of influenza. |
globenewswire.com |
2024-09-30 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks |
INTENDED FOR CANADIAN AUDIENCES ONLY TORONTO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for oral, once-daily PrORLADEYO® (berotralstat), which is approved in Canada for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. |
globenewswire.com |
2024-09-17 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium |
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making (SDM) between healthcare providers (HCPs) and their hereditary angioedema (HAE) patients to provide optimal patient outcomes. |
globenewswire.com |
2024-09-06 06:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 28,400 shares, and restricted stock units (RSUs) covering an aggregate of 20,025 shares, of BioCryst common stock. The options and RSUs were granted as of August 30, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-09-04 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst to Present at Upcoming Investor Conferences |
RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: |
globenewswire.com |
2024-08-22 11:00:00 |
Czytaj oryginał (ang.) |
| BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript |
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2024 Earnings Call Transcript August 5, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Conference Call Participants Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Chris Raymond - Piper Sandler Gena Wang - Barclays Maury Raycroft - Jefferies Stacy Ku - TD Cowen Jon Wolleben - JMP Securities Serge Belanger - Needham & Company Operator Good day and welcome to the BioCryst Second Quarter 2024 Earnings Call. All participants will be in listen-only mode. |
seekingalpha.com |
2024-08-05 15:44:09 |
Czytaj oryginał (ang.) |
| Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect? |
The mean of analysts' price targets for BioCryst (BCRX) points to a 99.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-08-05 15:01:20 |
Czytaj oryginał (ang.) |